A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Compounding pharmacies are supposed to stop producing the compounded versions of the popular weight loss medications now that ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Trump is “in peak physical and mental condition,” White House Press Secretary Karoline Leavitt told The Atlantic in an ...

joined ABC News Live to discuss the promising results from Eli Lilly's newly announced weight loss pill. Drug maker Eli Lilly says data from a late-stage trial showed a reduction in weight of ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Kennedy Jr. said that popular GLP-1 weight loss drugs -- Novo Nordisk's (NVO) Wegovy (semaglutide) and Eli Lilly's (NYSE ... the federal government will "no longer be subsidizing R&D for the ...

It is no longer Europe's most valuable ... deal to be listed as the preferred weight-loss drug for coverage on CVS's (CVS) formulary. This caused Lilly's stock to tank last week, but Jørgensen ...